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A B S T R A C T
The surface charge of brain endothelial cells forming the blood-brain barrier (BBB) is highly negative due to
phospholipids in the plasma membrane and the glycocalyx. This negative charge is an important element of the
defense systems of the BBB. Lidocaine, a cationic and lipophilic molecule which has anaesthetic and antiar-
rhytmic properties, exerts its actions by interacting with lipid membranes. Lidocaine when administered in-
travenously acts on vascular endothelial cells, but its direct eﬀect on brain endothelial cells has not yet been
studied. Our aim was to measure the eﬀect of lidocaine on the charge of biological membranes and the barrier
function of brain endothelial cells. We used the simpliﬁed membrane model, the bacteriorhodopsin (bR) con-
taining purple membrane of Halobacterium salinarum and culture models of the BBB. We found that lidocaine
turns the negative surface charge of purple membrane more positive and restores the function of the proton
pump bR. Lidocaine also changed the zeta potential of brain endothelial cells in the same way. Short-term
lidocaine treatment at a 10 μM therapeutically relevant concentration did not cause major BBB barrier dys-
function, substantial change in cell morphology or P-glycoprotein eﬄux pump inhibition. Lidocaine treatment
decreased the ﬂux of a cationic lipophilic molecule across the cell layer, but had no eﬀect on the penetration of
hydrophilic neutral or negatively charged markers. Our observations help to understand the biophysical back-
ground of the eﬀect of lidocaine on biological membranes and draws the attention to the interaction of cationic
drug molecules at the level of the BBB.
1. Introduction
Every biological membrane shares the same phospholipid bilayer
structure, where the hydrophobic fatty acid tail of the phospholipids
and the hydrophilic, ionized polar head groups line both surfaces and
create the basis of the surface charge of the cell membrane. This surface
charge can contribute to the passive or active permeability of ions and
metabolites [1,2]. Amphipathic drugs, like many anaesthetics interact
with the phospholipid bilayer membranes according to the bilayer
couple hypothesis which states that amphipathic drugs aﬀect cells by
the asymmetric insertion into one side of the lipid bilayer which in-
creases membrane ﬂuidity [3,4]. Lidocaine is a commercially available
tertiary amine used as local anaesthetic. In addition, this lipophilic drug
has anti-hyperalgesic, analgesic, anti-inﬂammatory properties and is
also used to treat cardiac arrhythmia [5–7]. Lidocaine after being in-
travenously injected dissociates to a positively charged quaternary
amine and to uncharged base forming an in vivo equilibrium between
the uncharged and charged molecules, which depends on the local pH
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[8]. Although the mode of action of local anaesthetics is not fully un-
derstood, it is clear that they interact with lipid membranes [9], change
the ﬂuidity, micro-viscosity and permeability [8,10]. Hypotheses for
the mode of action include that lidocaine might interact with mem-
brane proteins binding to the intracellular site of the voltage-gated
sodium channels blocking its action or just inserts to the membrane [9]
and interferes with the channel conductivity by changing its shape
[8,11,12]. The most accepted theory is that lidocaine inserts to speciﬁc
binding sites in the membrane, and by its charge blocks the Na+ current
across the cell membrane [11].
Bacteriorhodopsin (bR) is a good simpliﬁed model to investigate
charge-related changes of biological membranes. bR is a seven trans-
membrane-helix light driven proton pump with a covalently bound
retinal chromophore, found in the cell membrane of Halobacterium
salinarum, forming purple patches, the so called “purple membrane”
[13]. The purple color of the chromophore of bR can be converted to
blue, reﬂecting the inhibition of the proton pump, by two methods:
either by removing divalent cations bound to the purple membrane (the
“deionized blue” from) [14] or lowering the pH by sulfuric acid solution
(the “acid blue” form below pH 3.1–3.2) [15]. The functional bR can be
restored either by the addition of cations or raising the pH. It has been
shown that cationic lidocaine is able to restore the purple color and the
function of the proton pump in deionized bR [16,17], but its eﬀect on
acid blue bR has not yet been investigated.
Brain endothelial cells form the morphological basis of the blood-
brain barrier (BBB) together with pericytes and glial endfeet, and are
key elements in maintaining and regulating the homeostasis of the
central nervous system [18,19]. The most important parts of the phy-
sical barrier of the BBB are the interendothelial tight junctions (TJs)
and the negative surface charge of brain endothelial cells. This negative
charge is derived from the endothelial glycocalyx composed of sialo-
glycoconjugates and heparan sulfate proteoglycans [20,21] and the
special lipid composition of the plasma membrane of brain endothelial
cells [22]. In contrast to other cell types, the negatively charged
phosphatidylserine and phosphatidilcholine were the most abundant in
endothelial cells from brain [22]. The negative surface charge con-
tributes to the regulation of the permeability for positively charged
molecules at the BBB [21,22].
Lidocaine is administered intravenously to treat cardiac arrhythmia
[6], therefore it interacts directly with vascular endothelial cells, in-
cluding brain capillary endothelial cells. According to previous studies
lidocaine aﬀects the electrostatic potential of lipid bilayers: the charged
molecular form acts at the lipid headgroups, while the uncharged mo-
lecule increases the electrostatic potential in the middle of the mem-
brane [23,24]. In the present study our aim was to understand how
lidocaine interacts with cell membranes using a simple membrane
system containing bR and cell culture models of the BBB. We are the
ﬁrst to study the direct action of lidocaine on the surface charge of brain
endothelial cells and their function including electrical resistance and
permeability. The endothelial surface charge and its relationship to
barrier function is an underresearched area of the BBB ﬁeld. We hy-
pothesized that lidocaine, a cationic drug molecule, can directly inﬂu-
ence the permeability of charged molecules across the BBB.
2. Methods
2.1. Animals
Organ harvest from animals was performed according to the reg-
ulations of the 1998. XXVIII. Hungarian law and the EU Directive 2010/
63/EU about animal protection and welfare. The local animal health
authority, the Governmental Oﬃce for Csongrád County, Directorate of
Food Chain Safety and Animal Health approved our studies (Permit
numbers: XVI/834/2012). For primary cell isolations brain tissues were
obtained from 4-week old and 1-day-old Wistar rats (Harlan
Laboratories, United Kingdom) of both sexes. Animals were kept under
a 12 h light/dark cycle and fed on standard rodent chow and water ad
libitum in the conventional animal house of the Biological Research
Centre. Following the 3R-rule all eﬀorts were made to minimize animal
suﬀering and pain.
2.2. Materials
All reagents were purchased from Sigma-Aldrich Ltd. Hungary (part
of Merck Life Science), unless otherwise indicated.
2.3. Treatments
All treatments performed on bR or in vitro cell cultures were done
using a stock solution of lidocaine (20mM, Sigma L7757). Lidocaine
was dissolved in water at 30 °C. Stocks were always prepared freshly
before each experiment.
2.4. Bacteriorhodopsin assays
2.4.1. Preparation of purple membrane
Purple membranes containing bR were isolated as described pre-
viously [13] from Halobacterium salinarum strain R1, which homo-
logously expresses wild type bR and does not tend to form vacuoles,
thereby facilitating the isolation procedure. Cultures of H. salinarum
archaebacteria were grown for about 70–90 h in a shaking incubator,
then the culture was centrifuged, pelleted and re-suspended in 200ml
of 25% NaCl solution with 5mg of DNase. After dialysis against distilled
water (DW) the red clear lysate was centrifuged (30min at 50000g) and
a purple pellet was obtained. To separate the purple membranes from
other fragments the pellet was washed once with 4.3 M NaCl, once with
0.1 M NaCl and ﬁnally with DW. In the end the purple membrane was
centrifuged in a concentration gradient of sucrose from 0.5 to 1.5M for
10 h at 200000g in order to remove the red material. From 10 l of
bacteria suspension 300–500mg of purple membrane is gained.
2.4.2. Preparation of polyacrylamide gels
The eﬀects of lidocaine were studied on purple membranes which
were immobilized in 0.1% polyacrylamide gel as described previously
[25]. Brieﬂy, the gels were prepared using the combination of two so-
lutions. First, tetramethyl-ethylene-diamine (TEMED, Serva, Hungary)
was added to the purple membrane suspension with a ﬁnal dilution of
0.35% (v/v) to prepare the ﬁrst solution with an optical density (OD) of
4. Then 30% acrylamide/bis mixture (BioRad, Hungary) was prepared
containing ammonium persulfate (Serva, Hungary) at a ﬁnal con-
centration of 0.1% (v/v). At the end the two solutions were combined
and poured into a mould where it polymerized and remained in DW for
24 h.
2.4.3. Treatment of polyacrylamide gels containing purple membrane
Gels containing purple membranes were incubated with diﬀerent
concentrations of lidocaine. For this treatment lidocaine solutions of 10
and 1mM were prepared in 0.5mM H2SO4 (pH 3.0–3.2). The gel slabs
(4×4×20mm in dimension) were soaked in glass ﬂasks containing
15ml of each treatment solution at 4 °C in the dark for a minimum of
24 h. After the incubation photocycle measurement was performed
[26], where a blank gel that did not contain bR was used as a reference.
The gel samples were placed in rectangular plastic cuvettes with both
the measuring light and the perpendicular exciting laser light crossing
through 4mm pathlengths. The temperature of the samples was kept at
20 °C during the measurements. Absorption spectra of the samples were
taken with a ScanSci miniature spectrophotometer [UNICAM UV/Vis
Spectrometer UV4] prior to the photocycle measurement. Time re-
solved diﬀerence spectra after the exciting laser pulse (Continuum
Surelight Nd-YAG laser+OPO, appr. 10 ns pulse width) were taken
using home built timing and triggering units and an Andor iStar gated
CCD detector attached to a Jobin Yvon HR300 spectrograph. The white
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measuring light from a 35W Hamamatsu high pressure Xe light source
was chopped with a Uniblitz shutter to provide illumination for several
tens of milliseconds only during a measuring cycle of 3 s. For the sample
in 10mM lidocaine solution, pH 3.0, 560 nm, for that without lidocaine,
at pH 3.0, 630 nm laser pulses were applied in the several 100 μJ range.
Diﬀerence spectra were measured on a logarithmically equidistant
manner from 250 ns to 630ms with 5 spectra per decade.
2.5. Cell cultures
2.5.1. Blood-brain barrier models
2.5.1.1. hCMEC/D3 human brain endothelial cell line. The human
hCMEC/D3 brain endothelial cell line [27] was purchased from
Merck Millipore. The cultures of hCMEC/D3 (≤passage number 35)
were grown at 37 °C, 5% CO2 in MCDB 131 medium (Pan Biotech)
supplemented with 5% fetal bovine serum (FBS), GlutaMAX (100×,
Life Technologies, USA), lipid supplement (100×, Life Technologies,
USA), 10 μg/ml ascorbic acid, 550 nM hydrocortisone, 100 μg/ml
heparin, 1 ng/ml basic ﬁbroblast growth factor (bFGF, Roche, USA),
5 μg/ml insulin-transferrin‑selenium (ITS) supplement (100×,
PanBiotech, Germany), 10mM HEPES and gentamycin (50 μg/ml).
Medium change was performed every two or three days. When cells
reached a conﬂuence of 90% they were passaged for transendothelial
electrical resistance (TEER) measurements and permeability assays to
rat tail collagen-coated Transwell clear inserts (#3460, 0.4 μM pore
size, polyester membrane, Corning Costar), for the zeta measurements
to 60mm Petri dishes (Corning Costar, USA) and for the viability assays
to 96-well plates (E-plate, ACEA Biosciences, USA or Corning Costar,
USA) Before each experiment the medium was supplemented with
10mM LiCl for 24 h to improve BBB properties [28].
2.5.1.2. Primary cell cultures. The isolation of primary rat brain
endothelial cells (RBEC), glial cells and pericytes and the construction
of the in vitro BBB model were done according to the method described
in our previous studies [29,30]. After isolation, primary brain
endothelial cells were seeded on petri dishes (Corning Costar, USA)
coated with 100 μg/ml collagen type IV and 100 μg/ml ﬁbronectin in
sterile distilled water. The cells were cultured in DMEM/F-12 (Gibco,
Life Technologies, USA), 15% plasma derived bovine serum (PDS, First
Link, UK), 100 μg/ml heparin, 5 μg/ml insulin, 5 μg/ml transferrin,
5 ng/ml sodium selenite (ITS), 1 ng/ml bFGF (Roche, USA), 10mM
HEPES and 50 μg/ml gentamicin. For the ﬁrst 3 days of culture 3 μg/ml
puromycin was added to the base medium to eliminate P-glycoprotein
negative, contaminating cell types [31].
The primary rat brain pericytes were isolated using the same
method as described previously, except that pericytes were seeded to
uncoated petri dishes (Corning, Costar, USA). Primary cultures of glial
cells were prepared from one-day-old Wistar rats and passaged to 12-
well plates (Corning, Costar, USA) coated with 100 μg/ml collagen type
IV in sterile distilled water. Cultures of rat glial cells were maintained
for 2 weeks before using them for the triple co-culture model. The
pericytes and glial cells were kept in low glucose DMEM (Gibco, Life
Technologies, USA) supplemented with 10% FBS (Gibco, Life
Technologies, USA) and 50 μg/ml gentamicin.
The triple co-culture of the primary cells was assembled as de-
scribed before [29]. Brieﬂy, pericytes at passage number two were
seeded at a density of 1.5× 104/cm2 to the bottom of the membranes
of Transwell clear cell culture inserts, while RBECs were passaged to the
top of the membranes at a number of 7.5× 104/cm2. The inserts were
placed into the 12-well plates containing the glial cultures. The triple
BBB co-culture model received endothelial culture medium supple-
mented with 550 nM hydrocortisone and it was cultured together for 4
to 5 days [29]. After the in vitro BBB model was established TEER
measurements, permeability assays and immunohistochemistry were
performed. One day before the permeability assay cells were treated
with chlorophenylthio-adenosine-3,5-cyclic monophosphate (250 μM,
CPT-cAMP) and phosphodiesterase inhibitor RO 201724 (17.5 μM,
Roche) to tighten junctions and elevate resistance [31,32].
2.5.2. PC-3 human prostate cancer cell line
The PC-3 cell line was purchased from the American Type Culture
Collection (ATCC, USA). The cells were cultured in RPMI medium
(Gibco), supplemented with 10% FBS and 1% penicillin-streptomycin
solution. The cultures were kept in a 10 cm petri dish until reaching
80–90% of conﬂuency, then they were trypsinized and used for the zeta
measurements.
2.6. Cell viability assays
2.6.1. Impedance measurement
Kinetics of the viability of brain endothelial cells after lidocaine
treatment was monitored by real time impedance measurement (RTCA-
SP, ACEA Biosciences, San Diego, CA, USA). Impedance measurement
correlates linearly with cell number, adherence, growth and viability
[30]. Brain endothelial cells (hCMEC/D3 and RBECs) were seeded at a
cell number of 5× 103/well onto a 96-well E-plate (ACEA Biosciences)
with golden electrodes at the bottom of the wells, and were kept in the
CO2 incubator at 37 °C for 4–5 days, and treated at the beginning of the
plateau phase of cell growth with 0, 1, 3, 10, 30, 100, 300 and 1000 μM
concentrations of lidocaine. Triton X-100 detergent was used to de-
termine 100% toxicity. Eﬀects of the treatment were followed for 24 h.
2.6.2. MTT and lactate dehydrogenase release assays
For these assays brain endothelial cells (hCMEC/D3 and RBECs)
were seeded onto 96-well plates (Corning Costar, USA) at a cell number
of 5×103/well. Conﬂuent cultures were treated with 0–1000 μM of
lidocaine or for 30min, Triton X-100 was used as a 100% cytotoxic
control.
Viable cells convert the yellow MTT dye (3-(4,5-dimethylthiazol2-
yl)-2,5-diphenyltetrazolium bromide) to purple formazan crystals re-
ﬂecting metabolic activity. After lidocaine treatment MTT solution
(0.5 mg/ml) was added and cells were incubated for 3 h at 37 °C.
Formazan crystals produced by living cells were dissolved with di-
methyl sulfoxide, and absorbance was measured at 570 nm by a mul-
tiwell microplate reader (Fluostar Optima, BMG Labtechnologies,
Germany). Cytotoxicity was calculated as a percentage of the control
where the maximum dye conversion was detected.
In order, to investigate membrane damage the presence of in-
tracellular lactate dehydrogenase (LDH) enzyme was determined from
the supernatant using a commercially available kit [33]. After treat-
ment, culture supernatants (50 μl) were collected into another 96-well
plate and were incubated with equal amounts of reaction mixture for
15min on a horizontal shaker according to the manufacturer's protocol
(Cytotoxicity detection kit LDH, Roche). Enzyme reaction was stopped
with 0.1M of HCl and absorbance was measured at 450 nm wavelength
using a multiwell microplate reader (Fluostar Optima, BMG Lab-
technologies, Germany). Cytotoxicity was calculated as a percentage of
the total LDH release from cells treated with 1% Triton X-100 de-
tergent.
2.7. Zeta potential measurements
The zeta potential (ζ) was measured by dynamic light scattering
using a Zetasizer Nano ZS instrument (Malvern, UK) equipped with a
He-Ne laser (λ=632.8 nm). The zeta-potential of the samples was
measured at 25 °C, from a minimum of 6 measurements (maximum 100
runs each), with an applied 20 or 40 V voltage, using disposable zeta
potential cells with gold-coated platinum electrodes (DTS1070,
Malvern, UK) [22]. Before measurements the zeta cuvettes were acti-
vated once with 100% ethanol and rinsed twice with distilled water.
After activation, the zeta cuvettes were calibrated with the zeta stan-
dard solution (Malvern, UK) as described in the manufacturer's
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protocol. For purple membrane samples, the zeta potential measure-
ments were performed at OD=0.1 diluted in 0.5mM sulfuric acid.
Treatment of purple membrane samples was performed with 10mM
lidocaine for 30min. Cuvettes were always rinsed twice with distilled
water between measurements. The hCMEC/D3 and RBEC brain en-
dothelial cells, and PC-3 human prostate cancer cells were used for zeta
measurements after cultures reached 90% conﬂuency. Trypsinization of
the cells was performed very quickly to minimize plasma membrane
changes. After trypsinization, 105 cells were re-suspended in 1ml of
PBS with Ca2+ and Mg2+. Cells were treated with diﬀerent con-
centrations of lidocaine (10, 100 and 1000 μM) for 30min before the
measurement at 37 °C. The Zetasizer Software v.7.12. calculated the
zeta potential values using the Smoluchowski equation [34]:
=ζ 4πμη
ε
where μ represents the electrophoretic mobility, η the viscosity of the
solvent and ε the dielectric constant.
2.8. Evaluation of barrier integrity
2.8.1. Transendothelial electrical resistance
The BBB models (hCMEC/D3 and the primary cell based co-culture)
prepared on inserts received fresh culture medium every second day. To
follow the development of the barrier properties of the brain en-
dothelial monolayers TEER was measured before every medium change
with an EVOM voltohmmeter (World Precision Instruments Inc., USA)
combined with STX-2 electrodes. TEER was expressed relative to the
surface of the inserts (Ω×cm2). The TEER of cell-free inserts
(100Ω×cm2) was subtracted from the measured values. TEER before
and after lidocaine treatment was measured in Ringer-Hepes buﬀer
supplemented with 1% BSA and ITS. This buﬀer had the same com-
position as used for the permeability measurements. To decrease ﬂuc-
tuations in the TEER due to temperature change measurements were
performed by placing the culture plates to a heating pad set to 37 °C.
2.8.2. Permeability measurement with marker molecules of diﬀerent surface
charge
Permeability tests on the BBB models on inserts were performed
when TEER values reached previously published values (86 ± 9,
n=24 for D3, 255 ± 15 for RBEC n=24 co-culture; [35]), showing
the barrier properties for both models. For the permeability experi-
ments inserts were transferred to 12-well plates containing 1.5ml
Ringer-HEPES buﬀer (118mM NaCl, 4.8mM KCl, 2.5mM CaCl2,
1.2 mM MgSO4, 5.5mM D-glucose, 10mM HEPES, pH 7.4) supple-
mented with 1% BSA and ITS in the lower (basal/abluminal) com-
partment. In the upper (apical/luminal) compartment culture medium
was replaced with 0.5 ml buﬀer containing 10 μM lidocaine and mole-
cular markers with diﬀerent surface charges: FITC-dextran (10 μg/ml,
FD, Mw: 10 kDa) with neutral charge, positively charged rhodamine123
(10 μM, R123, Mw: 380 Da) and negatively charged Lucifer yellow
(5 μM, LY, Mw: 457 Da). Cells serving as control were only incubated
with the ﬂuorescent markers without any lidocaine treatment. The
plates were kept in a CO2 incubator at 37 °C on a horizontal shaker
(150 rpm) for 30min. After incubation the samples were collected from
the compartments and the concentrations of the marker molecules were
determined by a spectroﬂuorometer (Horiba Jobin Yvon Fluorolog 3,
Kyoto, Japan). Excitation/emission values for the diﬀerent markers
were: 440 nm/516 nm for FD; 498 nm/525 nm for R123; 420 nm/
535 nm for LY.
Transendothelial permeability coeﬃcient (Pe) was calculated as
previously described [29,30]. Brieﬂy, clearance was calculated from the
transport of the ﬂuorescent marker molecule from the donor to the
acceptor compartment expressed as μl of donor compartment volume
from which the tracer was completely cleared. The average cleared
volume was plotted vs. time, and permeability surface area product
value for endothelial monolayer (PSe) was calculated by the following
formula:
= −
PS PS PS
1 1 1
endothelial total insert
PSe was normalized for the surface area of the Transwell insert
(1.12 cm2) and was expressed as 10−6 cm/s. In measurements from the
apical to basal (AB) direction the upper compartment served as the
donor and the lower compartment as the acceptor. In the case of the
basal to apical (BA) direction the donor compartment was the lower,
while the acceptor compartment was the upper one.
2.8.3. Immunohistochemistry
After the permeability assays brain endothelial cells were stained for
junctional associated proteins β-catenin and ZO-1 and for tight junction
protein claudin-5 to assess the morphological changes after lidocaine
treatment. Cells were ﬁxed with cold acetone-methanol solution (1:1)
for 2min, washed with phosphate buﬀered saline (PBS) and non-spe-
ciﬁc binding sites were blocked with 3% bovine serum albumin (BSA)
in PBS for 1 h at room temperature. Incubation with primary antibodies
(dilution 1:200) polyclonal rabbit anti-β-catenin (Sigma C2206), poly-
clonal rabbit anti-ZO-1 (Invitrogen, 61–7300) and polyclonal rabbit
anti-claudin-5 (Sigma, SAB4502981) lasted overnight at 4 °C. The next
day cells were incubated with anti-rabbit secondary antibody labeled
with Cy3 (Sigma C2306; dilution 1:400), and bis-benzimide H33342
(Merck, Germany) to stain nuclei, for 1 h at room temperature. Between
incubations cells were washed three times with PBS. Stainings were
visualized by a Leica TCS SP5 confocal laser scanning microscope (Leica
Microsystems, Germany). Pictures for the junctional-cytoplasm in-
tensity ratio evaluations were taken with the exact same settings among
cell types and stainings.
2.9. Image analysis
The ﬂuorescently labeled images were analysed using Matlab soft-
ware (R2019a, MathWorks, Inc.). In brain endothelial cells the ﬂuor-
escent intensity of the immunostaining for junctional proteins in the
cell membrane is higher than in the cytoplasm. First we determined the
cytoplasmic intensity, from which binary images (BIs) were created.
The complementary BIs were considered as the junctional staining in
the plasma membrane. The pixels in the two BIs were used as masks,
and the intensities of the original pixels were summed in both the
junctional BIs and the cytoplasmic BIs separately. The ratio of the cell
membrane and cytoplasm intensities for each image was determined
and used for the statistical analysis. The number of images were 11–15
in each group.
2.10. Measurement of eﬄux pump activity
The activity of the P-glycoprotein eﬄux pump was measured by
R123, a ligand of this transporter, similarly to the permeability assay,
but both in the AB and BA directions. For measurements in the BA di-
rection the donor compartment was the lower, while the acceptor
compartment was the upper one. As a reference Pgp pump inhibitor,
cyclosporin A (10 μM) was used (30min pre-treatment of cells). During
the assay cells were incubated for 30min with 10 μM R123 with or
without 10 μM lidocaine in Ringer-HEPES buﬀer. After the incubation
samples were collected from the upper and lower compartments and
the concentration of R123 in the samples was determined by a spec-
troﬂuorometer (Horiba Jobin Yvon Fluorolog 3; excitation/emission:
498/525 nm).
2.11. Statistics
Data are presented as means± SD. Statistical signiﬁcance between
treatment groups was determined using t-test, one-way or two-way
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ANOVA followed by Dunnett or Bonferroni multiple comparison post-
tests (GraphPad Prism 5.0; GraphPad Software, USA). All experiments
were repeated at least twice, and the number of parallel samples was
minimum three. Changes were considered statistically signiﬁcant at
p < 0.05.
3. Results
3.1. Eﬀect of lidocaine on the purple membranes
The chromophore of the bR is sensitive to the absence of divalent
cations bound to the purple membrane at neutral pH: upon removal of
divalent cations by deionizing the membrane suspension, the color of
bR changes from purple to blue, which is accompanied by inactivation
of the proton pump [14]. Purple membrane also turns blue, and the
proton pump is inhibited in sulfuric acid solution with pH below
3.1–3.2 [15]. This condition is shown on Fig. 1A when no lidocaine
treatment is present and the gels containing purple membrane turn blue
due to the acidic pH. Lidocaine treatment at 1 and 10mM concentra-
tions reversed this color change (Fig. 1A), an eﬀect that was con-
centration dependent.
Fig. 1B shows the absolute spectra of the samples with and without
10mM lidocaine treatment at pH 3.0. As observed also visually, the
sample without lidocaine was blue (pure blue) as expected at this pH
due to the protonation of the proton acceptor Asp85 already in the
resting state of the pigment. The sample treated with 10mM lidocaine
at pH 3.0 turned purple. The absorption spectrum of the latter has a
maximum close to the position expected at neutral pH, whereas that of
the blue membrane is substantially red shifted. As both spectra ap-
peared wider than the spectrum of bR at higher pH, we estimate that
both are mixtures of the pure purple and pure blue forms. An estimate
of 25/75% and 75/25% contribution of the purple and blue forms to the
zero and the 10mM lidocaine samples, respectively, yields narrower
calculated spectra of the two pure forms (Fig. 1B). Representative time
resolved diﬀerence spectra measured on the purple membrane con-
taining gel samples at pH 3.0, with and without 10mM lidocaine
treatment, are shown in Fig. 1C and D. The purple samples in 10mM
lidocaine display a regular photocycle typical at higher pH with con-
secutive L, M and O intermediates, with characteristic absorption peaks
seen at 6.3 μs after excitation at 410 nm (L); 400 μs, 410 nm (M) and
16ms, 640 nm (O), followed by the recovery of the initial bR state in
about 100ms. The amount of accumulated O in the 10–100ms range is
relatively high as expected for the “normal” photocycle below the
pKa= 5.8 of the proton release cluster [37], where proton release is
delayed to the very end of the cycle, coinciding with the decay of the O
intermediate. On the other hand, the photocycle without lidocaine is
characteristic of the truncated cycle of the blue membrane. Here M does
not accumulate since the proton acceptor Asp85 is already initially
protonated so that the Shiﬀ base cannot deprotonate. After the accu-
mulation of a small amount of L-like intermediate the photocycle ter-
minates faster than in the case of the purple membrane.
3.2. Modulation of surface charge of purple membranes
Due to the absence of a direct measurement for the surface charge,
to evaluate the electrostatic properties of membrane surface, zeta
Fig. 1. Eﬀects of lidocaine on the purple membrane. A: Photos of the gels
containing purple membrane in 0.5 mM sulfuric acid (pH=3.2) without and
after 1mM and 10mM lidocaine treatment. B: Absorption spectra of purple
membrane containing gels incubated with and without lidocaine (10mM;
pH=3.0) as well as the calculated spectra for the pure purple and blue forms
(see text). The arrows indicate the wavelength of the exciting laser pulses for
the two samples. C, D: Time resolved diﬀerence spectra of purple membranes in
polyacrylamide gel at pH 3.0, without (C) and with (D) 10mM lidocaine.
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potential can be determined [22]. We measured the zeta potential of
purple membranes in 0.5 mM sulfuric acid and found it highly negative
(−36.4 ± 0.4mV, Fig. 2). Lidocaine treatment for 30min changed this
value to more positive (−21.9 ± 0.3mV), indicating a direct action of
the cationic drug on the charge of membranes containing bR. This shift
in the charge can explain the changes we observed in the purple
membrane color (Fig. 1A) and the shift in the bR spectrum (Fig. 1B).
3.3. Eﬀect of lidocaine on cell viability in the BBB models
First, the eﬀect of lidocaine on the viability, metabolic activity and
membrane integrity was studied using the hCMEC/D3 cell line and
primary RBECs. Lidocaine at 1–300 μM concentrations did not cause
any drop in the cell impedance after 30min (Fig. 3A–B). At the 1000 μM
lidocaine treatment concentration impedance decreased after 30min,
but this decrease was temporary, reversible and cells recovered to the
viability level of the control within 2 h.
Incubation of the cell monolayers for 30min with lidocaine in the
concentration range of 1–1000 μM did not cause any alteration in the
metabolic activity of the cells indicating no cell damage by the MTT
conversion assay (Fig. 3C–D). To determine if lidocaine damages the
plasma membrane integrity LDH assay was performed. As shown in
Fig. 3E–F, the release of LDH from the brain endothelial cells did not
increase compared to the control. Triton X-100 detergent was used as a
reference compound to elicit 100% toxicity in all the assays (Fig. 3).
3.4. Lidocaine as a modulator of surface charge in living mammalian cells
We hypothesized that lidocaine can change the surface charge of
biological membranes which was conﬁrmed in our measurements of
zeta potential of purple membranes. To further investigate this phe-
nomenon, we tested the eﬀects of lidocaine on the zeta potential of
living mammalian cells. In this study we used single cell suspensions
from the hCMEC/D3 human brain endothelial cell line, primary RBECs
and the PC-3 prostate cancer cell line with or without 10, 100 and
1000 μM lidocaine treatment. The base zeta potential for all three cells
types was negative, −11.4 ± 1.3mV for the hCMEC/D3 cells
(Fig. 4A); −12.3 ± 1.2mV for the RBECs (Fig. 4B) and
−20.1 ± 0.9mV for the PC-3 cell line (Fig. 4C). Since lidocaine is
metabolized very quickly in the body by the liver, we chose the 30min
treatment window. The background zeta values became more positive
after treatment with increasing lidocaine concentrations in the case of
all three cell types (Fig. 4) proving that lidocaine interferes with the
surface charge of living cells as well.
3.5. Integrity of the BBB models after lidocaine treatment
In clinical patients toxic side eﬀects were only seen above 5 μg/ml
(21.7 μM) plasma concentration of lidocaine [38]. To use a clinically
relevant, but not toxic concentration of lidocaine, we selected the
10 μM for the barrier experiments.
The BBB restricts the movement of not only cells and large mole-
cules, but also ions [32]. The most common method to determine the
tightness of the barrier is to measure the TEER. Therefore, to investigate
the eﬀect of lidocaine on the barrier properties of the BBB models we
ﬁrst measured resistance. There was a three times diﬀerence between
the TEER values of the BBB models showing that the primary co-culture
model better restrict the movement ions as compared to the simpliﬁed
BBB model (Fig. 5A–B). Lidocaine treatment (10 μM, 30min) decreased
the TEER on both models. The TEER drop in hCMEC/D3 cells was 35%
(84 ± 6 to 55 ± 10Ω×cm2) while on the triple co-culture BBB
model it was only 17% (252 ± 19 to 211 ± 6Ω×cm2).
Since lidocaine modiﬁed the surface charge of biological mem-
branes, we hypothesized that the permeability of charged molecules
across the BBB models might also change. We used three diﬀerently
charged ﬂuorescent markers to determine their permeability across
brain endothelial cells after lidocaine treatment. In the hCMEC/D3 cell
line model the permeability for the water soluble negatively charged
marker LY and neutral marker FD did not change as compared to the
control group but the cationic molecule R123 showed an increased ﬂux
after lidocaine treatment (Fig. 5C). For the primary BBB co-culture
model (Fig. 5D), also no change was observed for the LY and FD, al-
though the Papp values of the markers were much smaller (LY: 1/10, FD:
1/3 of the Papp in hCMEC/D3 model) showing once more that the in-
tegrity of the barrier is stronger in the co-culture model. As compared to
the cell line model the permeability of the cationic marker, R123, de-
creased after lidocaine treatment (Fig. 5D). This result is in accordance
with our hypothesis, which presumes that the interference of lidocaine
with the membrane charge decreases the permeability of a lipophilic
cationic marker across the BBB if the paracellular pathway is closed.
To conﬁrm the eﬀects of lidocaine on brain endothelial barrier in-
tegrity, immunostainings were performed for junctional proteins β-ca-
tenin, ZO-1 and claudin-5 (Fig. 6A–B). We evaluated the subcellular
expression of junctional proteins after lidocaine treatment with ﬂuor-
escent intensity measurements (Fig. 6C–D). In the control groups of
both BBB models the immunostainings were mainly located at the cell
borders, where the cell junctions are found. RBECs showed elongated
morphology with close cell-cell contacts (Fig. 6B). After 10 μM lido-
caine treatment a slight morphology change was visible in both models.
The β-catenin showed a cytoplasmic rearrangement both in the
hCMEC/D3 and the RBEC models. Similar change was observed for ZO-
1 in the hCMEC/D3 cells. Claudin-5 was not detectable in this cell line
Fig. 2. Modulation of surface charge of purple membrane. Zeta potential of
purple membrane in 0.5 mM H2SO4 (pH=3.2) without and with 10mM lido-
caine treatment (30min). Values of each group are presented as mean ± SD,
n= 10. Data were analysed by unpaired t-test. ****p < 0.0001, compared to
the untreated control.
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Fig. 3. Cell viability assays on the eﬀects of lidocaine on brain endothelial cells. Treatments were performed for 30min with concentrations of 1–1000 μM. TX: Triton
X-100 detergent served as positive control. A–B: Impedance measurements on hCMEC/D3 human brain endothelial cell line and on primary rat brain endothelial cells
(RBEC). C–D: The eﬀects of lidocaine on MTT dye conversion reﬂecting metabolic activity. E–F: Lactate dehydrogenase (LDH) release after lidocaine treatment
reﬂecting membrane integrity. Values of each group are presented as mean ± SD, n=6–8. Data were analysed by one-way ANOVA followed by Bonferroni post-test.
***p < 0.001, ****p < 0.0001 compared to the untreated control.
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(see Fig. S1 in Supplementary material). RBEC showed a redistribution
of the claudin-5 tight junction protein after lidocaine treatment which
is also reﬂected by the modest TEER decrease (Fig. 5).
3.6. Lidocaine is not an eﬄux pump blocker
Since R123 is not only a positively charged lipophilic compound,
but also a ligand of the Pgp eﬄux pump, we wanted to further in-
vestigate, whether lidocaine interferes with the activity of the Pgp
function. Bidirectional permeability assay was performed, which
showed that cyclosporin A by blocking Pgp increased the R123 ﬂux in
AB direction and decreased it in the opposite direction across the pri-
mary cell based BBB model (Fig. 7). In contrast, lidocaine treatment
(10 μM, 30min) decreased the permeability of R123 across RBECs from
the AB direction and did not change the ﬂux from the BA direction,
indicating that lidocaine does not inhibit the activity of the Pgp eﬄux
pump.
4. Discussion
The BBB has special defense systems constituted by the TJs, the
eﬄux pumps and the metabolic enzymes of brain endothelial cells
[19,39]. This line of defense is strengthened by the negative surface
charge of brain endothelial cells which regulates the entrance of
charged molecules through the BBB [21,40,41], but this area is not
extensively studied. In our experiments we investigated the eﬀects of
lidocaine on the surface charge of brain endothelial cells, which gets
into the systemic circulation as an antiarrhythmic drug [6], and can
have a direct eﬀect on the vascular system. Previous in vivo studies have
shown that lidocaine protects the BBB in high blood pressure caused
barrier opening [42] or in peripheral nerve damage [43]. However, its
eﬀect on the surface charge and the barrier properties of brain micro-
vessel endothelial cells have not yet been described. This study is the
ﬁrst to reveal the direct eﬀects of lidocaine on the surface charge of
biological membranes and its eﬀects on the permeability of BBB models
contributing to a wider knowledge on the interaction of cationic mo-
lecules at the level of BBB. To generalize the eﬀects on surface charge
and function, in addition to the hCMEC/D3 human brain endothelial
cell line and a primary rat brain endothelial cell based culture models
we also used purple membrane as a simple membrane system.
According to our hypothesis, lidocaine can inﬂuence the surface charge
of the brain endothelial cell membrane and by this it can also aﬀect BBB
function.
4.1. The eﬀect of lidocaine on purple membranes as a simple model system
The lipid content in the isolated purple membrane is about 25%.
Sulphated glycolipids are exclusively found in the purple membrane,
and they are responsible for the negative charge [44]. Lidocaine
treatment for 30min had a direct action on the bR: a shift in both the
purple membrane charge and the bR spectrum occurred (Fig. 1A and
Fig. 1B). The blue color of the gels containing purple membrane was
triggered by the low pH that also inhibits bR function (Fig. 1A). When
the pH is low, the large amount of protons compensate the negative
surface charge of purple membranes and provoke protonation of a
crucial side chain of bR stopping its pumping action [15]. When lido-
caine is added, it substitutes protons at the membrane surface, and
allows bR to function again. The absorption spectrum and the photo-
cycle of bR at pH 3.0 were typical for the acid blue membrane [13].
This result is similar to previous observations on deionized bR, where
the deactivation of the proton pump was achieved at pH 7 by the re-
moval of the divalent metal ions bound to the membrane, and the eﬀect
was reversed by cationic amine anaesthetics, including lidocaine [17].
Note, however, that in the latter caser purple color can be restored by
any other common cations as well [14]. Based on the zeta potential
measurements and the spectral data one can conclude that lidocaine
acts as a local factor increasing the pH close to the membrane surface by
at least 1–2 units, thereby aﬀecting the protonation state of even buried
residues of the protein. The decay of O intermediate, that coincides
with the recovery of the initial state is nevertheless substantially slower
than the recovery at neutral pH, indicating that this step involves the
direct extracellular proton release from Asp85 rather than the internal
proton transfer from Asp85 to the proton release cluster. Hence the
latter remains protonated during the photocycle as expected at eﬀective
pH values below the pKa= 5.8 of the proton release cluster [37].
4.2. The eﬀect of lidocaine on the viability of brain endothelial cells
After we conﬁrmed our hypothesis that lidocaine can inﬂuence the
surface charge, hence the function, of a simple biological membrane,
Fig. 4. Eﬀects of lidocaine on the surface charge of living mammalian cells. Cell cultures of the human brain endothelial cell line hCMEC/D3 (A), rat primary brain
endothelial cells (RBEC) (B), and human PC-3 prostate cancer cell line (C) were treated with diﬀerent concentrations of lidocaine for 30min to measure changes in
the surface zeta potential. Values of each group are presented as mean ± SD, n= 10–29. Data were analysed by one-way ANOVA followed by Bonferroni post-test.
#p < 0.05, **;##p < 0.01, ***p < 0.001, ****p < 0.0001 compared to the untreated control and between treatments.
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we were interested in the eﬀects of lidocaine on living cells. Lidocaine is
used in the pharmacotherapy as a local anaesthetic and has a clinically
important role in the treatment of abnormal heart rhythm [8,38]. When
given intravenously, it can act directly on brain endothelial cell mem-
branes and might aﬀect barrier properties of the BBB. To avoid the side
eﬀects of lidocaine, such as heart attack or neurologic symptoms, the
concentration of the lidocaine treatment should be optimized [38]. The
therapeutic plasma concentration of lidocaine is between 1.5 and 5 μg/
ml (6.5–22 μM). In order to determine the direct eﬀect of lidocaine on
the viability of brain endothelial cells, toxicity tests were performed. No
change was seen in any of the assays for the tested concentrations,
except for a reversible reduction of the impedance value at the highest,
suprapharmacological concentration of 1000 μM (Fig. 3). These data
are in accordance with the low toxicity and the safe applicability of
lidocaine as a therapeutic drug [6]. Since lidocaine is metabolized by
the liver within 2 h and the half-life of the drug is short in the blood
[6,38], we selected the clinically relevant 10 μM concentration and the
30-min treatment time to study the surface charge and barrier function
of the BBB models.
Fig. 5. Evaluation of the blood brain barrier (BBB) integrity on Transwell insert models of the BBB using hCMEC/D3 human brain endothelial cell line and rat
primary cell based triple co-culture model consisting of brain endothelial cells (RBEC) with pericytes and astroglia after lidocaine treatment (10 μM, 30min). A and B:
TEER measurements right before and 30min after the lidocaine treatment. Values of each group are presented as mean ± SD, n=5–12. Data were analysed by two-
way ANOVA followed by a Bonferroni post-test. ***p < 0.001, ****p < 0.0001, compared to the 0min. C and D: Endothelial permeability coeﬃcient (Pe) of cells
treated with lidocaine for three diﬀerently charged tracers: Lucifer Yellow (LY, −, negatively charged), Rhodamine 123 (R123, +, positively charged) and FITC-
Dextran (FD, 0, no charge). Values are presented as mean ± SD, n= 4. Data were analysed by unpaired t-test, where **p < 0.01; ***p < 0.001.
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4.3. The eﬀect of lidocaine on the surface charge of the brain endothelial
cells
While the hydrophobic interaction of lidocaine with the lipid bi-
layer of the cell membrane, including membrane ﬂuidity, and its in-
ﬂuence on protein channels has been studied [8,45], our study is the
ﬁrst to measure the eﬀect of this drug on surface charge of living cells.
In the vascular system the surface charge of brain endothelial cells is
more negative than that of peripheral endothelial cells [22]. This can be
explained by the special lipid composition of the plasma membrane of
brain microvascular endothelial cells [22] and the denser structure of
glycocalyx in the luminal surface of brain capillaries [46]. In con-
cordance with the ﬁrst measurement of the zeta potential of bovine
brain endothelial cell suspension [22], we also found that the surface
charge of human and rat brain endothelial cells are negative and in the
same range (Fig. 4). Lidocaine treatment, as we measured it on the
simple model system, made the zeta values of the cells more positive,
indicating a direct eﬀect on the surface charge in both models. The
surface charge elevation in mammalian cells after 1mM lidocaine
treatment (~40% from the control) was similar to the bR zeta potential
change caused by 10mM lidocaine. Since treatment of bR purple
membranes with the same concentration of lidocaine already resulted
in a considerable color change, we suggest a similar eﬀect in both
model systems. We have also tested lidocaine on a diﬀerent type of cell,
a human prostate cancer cell line, and found a similar eﬀect. Our data
on lidocaine and surface charge is supported by previous ﬁndings with
a cationic lipid probe, TMA-DPH. This probe, which inserts into the
plasma membrane of cells, made the zeta potential of brain endothelial
cells also more positive [22]. The role of the surface charge of mole-
cules, especially cationic ones, to cross the BBB has been long known
[21], but only recently measured [41]. The positively charged ibu-
profen-kyotorphinamide derivative not only increased the zeta poten-
tial of brain endothelial cells, but the molecule had an increased an-
algesic eﬀect in mice indicating higher penetration to brain [41].
4.4. The eﬀect of lidocaine on the barrier function of brain endothelial cells
The BBB restricts the transport of substrates, from ions to large
molecules, between the blood and the CNS [19]. The two major path-
ways for molecules and cells to cross the BBB are the paracellular
(junctional) and the transendothelial routes [32,39]. The TJs are im-
portant in permeability regulation, because they not only restrict
paracellular ﬂux, but also maintain polarity of enzymes and receptors
on the luminal and abluminal membrane domains [47]. The measure-
ment of TEER is the most sensitive method to assess the tightness of TJs
in BBB models [32,48]. The resistance of brain endothelial cell layers
was slightly, but signiﬁcantly decreased by lidocaine (Fig. 5A) sug-
gesting an increased paracellular ionic permeability. This change was
Fig. 6. A and B: Eﬀects of lidocaine treatment (10 μM, 30min) on β-catenin, ZO-1 and claudin-5 immunostaining in hCMEC/D3 human brain endothelial cell line and
rat primary brain endothelial cells. Red: staining for junctional proteins. Blue: H33342 staining of cell nuclei. Bar: 20 μm. C and D: Intensity ratio of the junctional and
the cytoplasmatic immunostainings. Values are presented as mean ± SD, n= 11–15. Data were analysed by unpaired t-test. *p < 0.05, **p < 0.01,
***p < 0.001, compared to the untreated control of the respective group.
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reﬂected by the redistribution of the immunostaining for three junc-
tional proteins, β-catenin, ZO-1 and claudin-5 in brain endothelial cells
from the plasma membrane to the cytoplasm after lidocaine treatment
(Fig. 6A–B) which was quantiﬁed by image analysis (Fig. 6C–D).
There was no signiﬁcant diﬀerence between the control and the li-
docaine treated groups in the permeability of the negatively charged
and hydrophilic markers, LY and FD (Fig. 5C–D). This result indicates
that lidocaine treatment aﬀects the paracellular pathway for ions, but
not for larger water-soluble molecules (for a more detailed explanation
and drawings see Figs. S2 and S3 in Supplementary material). The other
marker molecule, R123 is positively charged and lipophilic, therefore it
crosses a tight barrier by the transcellular pathway. If the barrier is not
tight, R123 is diﬀusing by both the trans- and the paracellular path-
ways. On the cell line BBB model the permeability of the R123 after
lidocaine treatment was increased (Fig. 5C). This can be explained by
the weaker barrier properties and the more dominant paracellular
pathway of the hCMEC/D3 cell line as compared to the primary cell
based BBB models [28,48], and as we conﬁrmed by the TEER data
(Fig. 5A). In the case of the primary brain endothelial cell co-culture
model, where TJs are tighter and the paracellular pathway is more
closed, as reﬂected by the several fold higher TEER, the permeability of
the cationic R123 was decreased by the positively charged lidocaine
(Fig. 5D). We suppose that there can be a physicochemical interaction
between lidocaine and R123, two positively charged molecules, at the
surface of brain endothelial cells decreasing the transcellular perme-
ability of R123 in the apical to basal direction (Fig. 8). In accordance
with our data, lidocaine decreased the permeability of cationic drugs
pentazocine and naloxone across the BBB in rats, but inﬂux drug
transport systems may participate in the brain uptake of these mole-
cules [49,50]. We cannot exclude the possibility, that other mechanisms
than membrane interactions also participate in the eﬀect of lidocaine on
BBB permeability.
Since R123 is a ligand of the Pgp eﬄux pump [29], one of the most
important eﬄux transporter at the BBB [19,48], we studied if lidocaine
has an eﬀect on Pgp activity. The action of lidocaine was opposite to
cyclosporine A, our reference inhibitor, suggesting that it does not in-
hibit the Pgp eﬄux pump (Fig. 8). Inhibition of Pgp did not change
brain/plasma concentration of lidocaine in rats [51] indicating that
lidocaine does not interact with the eﬄux pump, in agreement with our
ﬁnding.
5. Conclusion
Lidocaine, a cationic drug, made the surface charge of biological
membranes more positive in simple model membranes and in living
mammalian cells. This physical membrane eﬀect restored the proton
pump activity at acidic pH in purple membranes and altered the func-
tion of endothelial cells forming the barrier protecting the brain.
Lidocaine increased the ionic permeability of brain endothelial cell
layers, but the paracellular pathway did not change to water-soluble
marker molecules. In contrast, the permeability of a cationic lipophilic
marker was decreased, suggesting interaction of the cationic molecules
at the membrane level. Lidocaine had no eﬀect on the function of the
Pgp eﬄux pump. From these data, we can conclude that lidocaine can
change the surface charge, an important element of the defense func-
tion of the BBB. The more positive surface charge of brain endothelial
cells does not inﬂuence the permeability of the paracellular pathway for
hydrophilic molecules, but can restrict the permeability of lipophilic
cationic molecules via the transcellular pathway. Our observations on
one hand can help to understand the biophysical background of lido-
caine action, on the other hand draw attention to the drug interactions
at the level of the BBB.
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Fig. 7. Eﬀects of lidocaine on the P-glycoprotein eﬄux pump activity in pri-
mary rat brain endothelial cells (RBEC). Permeability of Rhodamine 123 (R123)
was measured from the abluminal to the luminal (A to B) and from the luminal
to the abluminal (B to A) compartment after 30min treatment with lidocaine or
1 h with P-glycoprotein pump inhibitor cyclosporin-A (CyA). Values are pre-
sented as mean ± SD n=4. Data were analysed by one-way ANOVA followed
by a Bonferroni post-test. *p < 0.05, **p < 0.01, ****, ####p < 0.0001,
compared to the control and between groups. C: Control, L: Lidocaine.
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